Clareo Health | An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Advances Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histological or cytological confirmation of pancreatic carcinoma who were not suitable for pancreatic tumour resection with curative intent
Patients who had not received chemotherapy in the previous month and who would either not receive chemotherapy in the period of study or who would commence gemcitabine treatment in week 4 of the study
Male or female patients over 18 years of age
Patients with a life expectancy of at least 2 months
Patients must have given written informed consent
Patients with a Karnofsky Performance Status score of ≥ 50%
Patients who would not receive chemotherapy in the period of the Extension Survival Study, except for concomitant gemcitabine ongoing at visit (for extension study)
You may not be if
History of other malignant disease except non-melanomatous skin carcinoma or in situ carcinoma of the uterine cervix
Concomitant use or anticipated use in the period of the study of radiotherapy
Chemotherapy in the previous month preceding screening, anticipated concomitant use of chemotherapy between screening and week 4 of the study or anticipated useof chemotherapeutic agents other than gemcitabine from week 4 for the period of the study
Use in the past month or concomitant use of immunosuppressants, including systemic (i.e. oral or injected) corticosteroids
Females who were pregnant, planning to become pregnant or lactating
Patients taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during the study
Haematological indicators:
Haemoglobin \<9.5g/dl White blood cell count \<3.5 x 109/l Platelets \<100 x 109/l
